The global Actinic Keratosis Treatment Market size is expected to reach USD 8.9 billion by 2030, registering a CAGR of 4.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.
Invasive
squamous cell carcinoma may develop from AK when it becomes malignant (iSCC).
Despite the fact that there are a number of potential causes for iSCC, AK is
one of the most frequent ones. Additionally, basal cell carcinoma and
non-melanoma skin cancer could result from AK. As a result, the demand for AK
products across sales channels is being driven by the early diagnosis and
treatment of actinic keratosis as a preventive strategy for comorbidities.
In
addition, future pipeline medications and the increased use of combination
therapy are key market drivers. For instance, Almirall, S.A. has Klisyri
(extended label) in phase III of R&D. Furthermore, a rise in the acceptance
and commercialization of innovative drugs is another factor that is predicted
to fuel market growth. Moreover, increased R&D activities are expected to
accelerate the approval of novel drugs used in the treatment of actinic
keratosis, hence, propelling the growth over the forecast period.
Key
players are adopting strategic initiatives such as product launches,
partnerships, and expansion strategies to increase their market share across
the globe. For instance, in June 2022, BIOFRONTERA AG announced that its
license and marketing authorization holder Louis Widmer SA based in Switzerland
has received an extension of its marketing authorization for the management of
actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in
July 2020, BIOFRONTERA AG announced that it has signed an agreement with
Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway,
Finland, Norway, and Iceland.
Related Press
Release@ Actinic
Keratosis Treatment Market Report
Actinic Keratosis Treatment Market Report Highlights
- Surgery held
the largest revenue share of 65.6% in 2022 owing to the rising adoption of
cryotherapy surgery in the management of actinic keratosis
- Nucleoside
metabolic inhibitors held the largest revenue share of 32.4% in 2022 and
is expected to retain its dominance over the forecast period
- Asia Pacific
is expected to grow at the fastest CAGR of 5.6% during the forecast period
due to factors such as the high prevalence of AK, rapidly evolving
healthcare infrastructure, and rising healthcare expenditures by Asia
Pacific countries
- North
America dominated the market with the largest revenue share of 41.5% in
2022 due to the rising awareness among people about actinic keratosis,
availability of robust treatment options, and improvements in healthcare
infrastructure
Actinic Keratosis Treatment Market Segmentation
Grand
View Research has segmented the global actinic keratosis treatment market on
the basis of therapy, drug class, end-use, and region:
Actinic Keratosis Treatment Therapy Outlook
(Revenue, USD Million, 2018 - 2030)
- Topical
- Photodynamic
Therapy
- Surgery
Actinic Keratosis Treatment Drug Class Outlook
(Revenue, USD Million, 2018 - 2030)
- Nucleoside
Metabolic Inhibitor
- NSAIDs
- Immune
Response Modifiers
- Photoenhancers
- Others
Actinic Keratosis Treatment End-use Outlook (Revenue,
USD Million, 2018 - 2030)
- Hospitals
- Private
Clinics
- Homecare
- Others
Actinic Keratosis Treatment Regional Outlook
(Revenue, USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
and Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment